Exposing the Underlying Relationship of Cancer Metastasis to Metabolism and Epithelial-Mesenchymal Transitions
Xin Kang, Jin Wang, Chunhe Li, Xin Kang, Jin Wang, Chunhe Li
Abstract
Cancer is a disease governed by the underlying gene regulatory networks. The hallmarks of cancer have been proposed to characterize the cancerization, e.g., abnormal metabolism, epithelial to mesenchymal transition (EMT), and cancer metastasis. We constructed a metabolism-EMT-metastasis regulatory network and quantified its underlying landscape. We identified four attractors, characterizing epithelial, abnormal metabolic, mesenchymal, and metastatic cell states, respectively. Importantly, we identified an abnormal metabolic state. Based on the transition path theory, we quantified the kinetic transition paths among these different cell states. Our results for landscape and paths indicate that metastasis is a sequential process: cells tend to first change their metabolism, then activate the EMT and eventually reach the metastatic state. This demonstrates the importance of the temporal order for different gene circuits switching on or off during metastatic progression of cancer cells and underlines the cascading regulation of metastasis through an abnormal metabolic intermediate state.
Keywords: Biological Sciences; Cancer; Cancer Systems Biology; Molecular Network.
Conflict of interest statement
The authors declare no competing interests.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Figures
References
- Agrawal N., Akbani R., Aksoy B.A., Ally A., Arachchi H., Asa S.L., Auman J.T., Balasundaram M., Balu S., Baylin S.B. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–690.
- Bocci F., Jolly M.K., George J.T., Levine H., Onuchic J.N. A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and notch-jagged signaling. Oncotarget. 2018;9:29906.
- Boroughs L.K., Deberardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015;17:351.
- Brabletz T., Kalluri R., Nieto M.A., Weinberg R.A. Emt in cancer. Nat. Rev. Cancer. 2018;18:128.
- Cancer Genome Atlas Research Network. Ley T.J., Miller C., Ding L., Raphael B.J., Mungall A.J., Robertson A., Hoadley K., Triche T.J., Jr., Laird P.W., Baty J.D. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013;368:2059–2074.
- Carmichael C.L., Goossens S., Wang J., Nguyen T., Haigh K., Berx G., Kile B., Haigh J.J. The EMT modulator snai1 drives AML development via its interaction with the chromatin modulator lsd1. Blood. 2016;128:2688.
- Chen C., Baumann W., Xing J., Xu L., Clarke R., Tyson J. Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. J. R. Soc. Interface. 2014;96:20140206.
- Chen K., Qian W., Li J., Jiang Z., Cheng L., Yan B., Cao J., Sun L., Zhou C., Lei M. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an hsf1-dependent pathway. Mol. Oncol. 2017;11:1475–1492.
- Cheong J.H., Park E.S., Liang J., Dennison J.B., Tsavachidou D., Nguyen-Charles C., Cheng K.W., Hall H., Zhang D., Lu Y. Dual inhibition of tumor energy pathway by 2-deoxy glucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 2011;10:2350–2362.
- Cho K.H., Lee S., Kim D., Shin D., Joo J.I., Park S.M. Cancer reversion, a renewed challenge in systems biology. Curr. Opin. Syst. Biol. 2017;2:49–58.
- Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J. Mammary Gland Biol. Neoplasia. 2010;15:253–260.
- Davudian S., Mansoori B., Shajari N., Mohammadi A., Baradaran B. Bach1, the master regulator gene: a novel candidate target for cancer therapy. Gene. 2016;588:30–37.
- Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.
- Ganapathy-Kanniappan S., Vali M., Kunjithapatham R., Buijs M., Syed L., Rao P., Ota S., Kwak B., Loffroy R., Geschwind J. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr. Pharm. Biotechnol. 2010;11:510–517.
- Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer. 2004;4:891.
- Ge H., Qian H. Landscapes of non-gradient dynamics without detailed balance: stable limit cycles and multiple attractors. Chaos. 2012;22:023140.
- Ge H., Qian H. Mesoscopic kinetic basis of macroscopic chemical thermodynamics: a mathematical theory. Phys. Rev. E. 2016;94:052150.
- Gibbons D.L., Lin W., Creighton C.J., Rizvi Z.H., Gregory P.A., Goodall G.J., Thilaganathan N., Du L., Zhang Y., Pertsemlidis A. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating mir-200 family expression. Genes Dev. 2009;23:2140–2151.
- Gill J.G., Piskounova E., Morrison S.J. Cancer, oxidative stress, and metastasis. Cold Spring Harb. Symp. Quant. Biol. 2016;81:163–175.
- Goldman A., Majumder B., Dhawan A., Ravi S., Goldman D., Kohandel M., Majumder P.K., Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat. Commun. 2015;6:6139.
- Goldman A., Khiste S., Freinkman E., Dhawan A., Majumder B., Mondal J., Pinkerton A.B., Eton E., Medhi R., Chandrasekar V. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci. Signal. 2019;12:eaas8779.
- Han T., Kang D., Ji D., Wang X., Zhan W., Fu M., Xin H.B., Wang J.B. How does cancer cell metabolism affect tumor migration and invasion? Cell Adh. Migr. 2013;7:395–403.
- Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000;100:57–70.
- Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
- Hong T., Watanabe K., Ta C.H., Villarreal-Ponce A., Nie Q., Dai X. An ovol2-zeb1 mutual inhibitory circuit governs bidirectional and multi-step transition between epithelial and mesenchymal states. PLoS Comput. Biol. 2015;11:e1004569.
- Huang S. Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev. 2013;32:423–448.
- Huang R., Zong X. Aberrant cancer metabolism in epithelial–mesenchymal transition and cancer metastasis: mechanisms in cancer progression. Crit. Rev. Oncol. Hematol. 2017;115:13–22.
- Huang S., Eichler G., Bar-Yam Y., Ingber D.E. Cell fates as high-dimensional attractor states of a complex gene regulatory network. Phys. Rev. Lett. 2005;94:128701.
- Ishay-Ronen D., Diepenbruck M., Kalathur R.K.R., Sugiyama N., Tiede S., Ivanek R., Bantug G., Morini M.F., Wang J., Hess C. Gain fat lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 2019;35:17–32.
- Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., Hayashi J.I. Ros-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–664.
- Jia D., Jolly M.K., Tripathi S.C., Den Hollander P., Huang B., Lu M., Celiktas M., Ramirez-Peña E., Ben-Jacob E., Onuchic J.N. Distinguishing mechanisms underlying EMT tristability. Cancer Converg. 2017;1:2.
- Jia D., Lu M., Jung K.H., Park J.H., Yu L., Onuchic J.N., Kaipparettu B.A., Levine H. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc. Natl. Acad. Sci. U S A. 2019;116:3909–3918.
- Jiang L., Xiao L., Sugiura H., Huang X., Ali A., Kuro-o M., Deberardinis R.J., Boothman D.A. Metabolic reprogramming during tgfβ 1-induced epithelial-to-mesenchymal transition. Oncogene. 2015;34:3908–3916.
- Jolly M.K., Boareto M., Huang B., Jia D., Lu M., Ben-Jacob E., Onuchic J.N., Levine H. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front. Oncol. 2015;5:155.
- Jolly M.K., Jia D., Boareto M., Mani S.A., Pienta K.J., Ben-Jacob E., Levine H. Coupling the modules of EMT and stemness: a tunable ’stemness window’ model. Oncotarget. 2015;6:25161–25174.
- Jolly M.K., Preca B.T., Tripathi S.C., Jia D., George J.T., Hanash S.M., Brabletz T., Stemmler M.P., Maurer J., Levine H. Interconnected feedback loops among esrp1, has2, and cd44 regulate epithelial-mesenchymal plasticity in cancer. APL Bioeng. 2018;2:031908.
- Kaern M., Elston T.C., Blake W.J., Collins J.J. Stochasticity in gene expression: from theories to phenotypes. Nat. Rev. Genet. 2005;6:451–464.
- Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009;119:1417–1419.
- Kamarajugadda S., Stemboroski L., Cai Q., Simpson N.E., Nayak S., Tan M., Lu J. Glucose oxidation modulates anoikis and tumor metastasis. Mol. Cell. Biol. 2012;32:1893–1907.
- Korpal M., Lee E.S., Hu G., Kang Y. The mir-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of e-cadherin transcriptional repressors zeb1 and zeb2. J. Biol. Chem. 2008;283:14910–14914.
- Lambert A.W., Pattabiraman D.R., Weinberg R.A. Emerging biological principles of metastasis. Cell. 2017;168:670–691.
- Lee J., Lee J., Farquhar K.S., Yun J., Frankenberger C.A., Bevilacqua E., Yeung K., Kim E.J., Balazsi G., Rosner M.R. Network of mutually repressive metastasis regulators can promote cell heterogeneity and metastatic transitions. Proc. Natl. Acad. Sci. U S A. 2014;111:E364–E373.
- Lee J., Yesilkanal A.E., Wynne J.P., Frankenberger C., Liu J., Yan J., Elbaz M., Rabe D.C., Rustandy F.D., Tiwari P. Effective breast cancer combination therapy targeting bach1 and mitochondrial metabolism. Nature. 2019;568:254.
- Li C. Identifying the optimal anticancer targets from the landscape of a cancer–immunity interaction network. Phys. Chem. Chem. Phys. 2017;19:7642–7651.
- Li C., Balazsi G. A landscape view on the interplay between EMT and cancer metastasis. NPJ Syst. Biol. Appl. 2018;4:34.
- Li C., Wang J. Quantifying cell fate decisions for differentiation and reprogramming of a human stem cell network: landscape and biological paths. PLoS Comput. Biol. 2013;9:e1003165.
- Li C., Wang J. Landscape and flux reveal a new global view and physical quantification of mammalian cell cycle. Proc. Natl. Acad. Sci. U S A. 2014;111:14130–14135.
- Li C., Wang J. Quantifying the underlying landscape and paths of cancer. J. R. Soc. Interface. 2014;10:20140774.
- Li C., Wang J. Quantifying the landscape for development and cancer from a core cancer stem cell circuit. Cancer Res. 2015;75:2607–2618.
- Li C., Hong T., Nie Q. Quantifying the landscape and kinetic paths for epithelial–mesenchymal transition from a core circuit. Phys. Chem. Chem. Phys. 2016;18:17949–17956.
- Liao C., Lu T. A minimal transcriptional controlling network of regulatory t cell development. J. Phys. Chem. B. 2013;117:12995–13004.
- Liao D., Corle C., Seagroves T.N., Johnson R.S. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007;67:563–572.
- Lu M., Jolly H., Levine H., Onuchic J., Ben-Jacob E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. Proc. Natl. Acad. Sci. U S A. 2013;110:18144–18149.
- Lu M., Jolly M.K., Onuchic J., Ben-Jacob E. Toward decoding the principles of cancer metastasis circuits. Cancer Res. 2014;74:4574–4587.
- Lu M., Onuchic J., Ben-Jacob E. Construction of an effective landscape for multistate genetic switches. Phys. Rev. Lett. 2014;113:078102.
- Lv C., Li X., Li F., Li T. Energy landscape reveals that the budding yeast cell cycle is a robust and adaptive multi-stage process. PLoS Comput. Biol. 2015;11:e1004156.
- Meyer S.E. From EMT to HSC to AML: Zeb2 is a cell fate switch. Blood. 2017;129:400–401.
- Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor snail promotes mammary tumor recurrence. Cancer Cell. 2005;8:197–209.
- Munozpinedo C., Mjiyad N.E., Ricci J. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3:e248.
- Ohashi S., Natsuizaka M., Wong G.S., Michaylira C.Z., Grugan K.D., Stairs D.B., Kalabis J., Vega M.E., Kalman R.A., Nakagawa M. Egfr and mutant p53 expand esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through zeb transcription factors. Cancer Res. 2010;70:4174.
- Pastushenko I., Brisebarre A., Sifrim A., Fioramonti M., Revenco T., Boumahdi S., Van Keymeulen A., Brown D., Moers V., Lemaire S. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463.
- Piskounova E., Agathocleous M., Murphy M.M., Hu Z., Huddlestun S.E., Zhao Z., Leitch A.M., Johnson T.M., DeBerardinis R.J., Morrison S.J. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527:186.
- Porporato P.E., Payen V.L., Pérez-Escuredo J., De Saedeleer C.J., Danhier P., Copetti T., Dhup S., Tardy M., Vazeille T., Bouzin C. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014;8:754–766.
- Powell E., Piwnica-Worms D., Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405–414.
- Qiu G., Lin Y., Zhang H., Wu D. mir-139-5p inhibits epithelial–mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting zeb1 and zeb2. Biochem. Biophys. Res. Commun. 2015;463:315–321.
- Sánchez-Tilló E., Siles L., De Barrios O., Cuatrecasas M., Vaquero E.C., Castells A., Postigo A. Expanding roles of zeb factors in tumorigenesis and tumor progression. Am. J. Cancer Res. 2011;1:897–912.
- Sciacovelli M., Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 2017;284:3132–3144.
- Singh A., Settleman J. Emt, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751.
- Stavropoulou V., Kaspar S., Brault L., Sanders M.A., Juge S., Morettini S., Tzankov A., Iacovino M., Lau I.J., Milne T.A. Mll-af9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016;30:43–58.
- Swain P.S., Elowitz M.B., Siggia E.D. Intrinsic and extrinsic contributions to stochasticity in gene expression. Proc. Natl. Acad. Sci. U S A. 2002;99:12795–12800.
- Tam W.L., Weinberg R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 2013;19:1438.
- Thattai M., Van O.A. Intrinsic noise in gene regulatory networks. Proc. Natl. Acad. Sci. U S A. 2001;98:8614–8619.
- Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.
- Trendowski M. The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy. Crit. Rev. Oncol. Hematol. 2015;94:149–163.
- Waddington C.H. Allen and Unwin; 1957. The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology.
- Wang J. Landscape and flux theory of non-equilibrium dynamical systems with application to biology. Adv. Phys. 2015;64:1–137.
- Wang J., Xu L., Wang E.K. Potential landscape and flux framework of non-equilibrium networks: robustness, dissipation and coherence of biochemical oscillations. Proc. Natl. Acad. Sci. U S A. 2008;105:12271–12276.
- Wang J., Zhang K., Xu L., Wang E.K. Quantifying the Waddington landscape and biological paths for development and differentiation. Proc. Natl. Acad. Sci. U S A. 2011;108:8257–8262.
- Wang L., Wu X., Wang B., Wang Q., Han L. Mechanisms of mir-145 regulating invasion and metastasis of ovarian carcinoma. Am. J. Transl. Res. 2017;9:3443.
- Ye X., Weinberg R.A. Epithelial–mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25:675–686.
- Yu L., Lu M., Jia D., Ma J., Ben-Jacob E., Levine H., Kaipparettu B.A., Onuchic J.N. Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. Cancer Res. 2017;77:1564–1574.
- Zhang B., Wolynes P.G. Stem cell differentiation as a many-body problem. Proc. Natl. Acad. Sci. U S A. 2014;111:10185–10190.
- Zhang J., Tian X., Zhang H., Teng Y., Li R., Bai F., Elankumaran S., Xing J. TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci. Signal. 2014;7:ra91.
- Zhao H., Kang X., Xia X., Wo L., Gu X., Hu Y., Xie X., Chang H., Lou L., Shen X. mir-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am. J. Transl. Res. 2016;8:3106.
Source: PubMed